TP
Tetragon Partners GP Ltd
13F filer · CIK 0001515070Reported Aug 13, 2026
Net buyer this quarter
13F portfolio value$635MU.S. long equity reported on 13F
Positions325 new · 7 closed
Net flow last quarter+$78.4MBuys minus sells
Top 10 positions weight74.0%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 13, 202632 positions | |||||
| $336M | 52.98% | Not reported | +22.8% | Q1 2022 | |
| $33.8M | 5.33% | 19.27% | Not reported | Q4 2023 | |
| $15.2M | 2.39% | 3.57% | Not reported | Q2 2018 | |
| $14.6M | 2.30% | 0.26% | Not reported | Q3 2019 | |
| $13.5M | 2.13% | 0.21% | +43.5% | Q1 2026 | |
| $12.1M | 1.91% | Not reported | Not reported | Q2 2025 | |
| $11.4M | 1.79% | 2.30% | Not reported | Q1 2022 | |
| $11.2M | 1.77% | 0.42% | +39.9% | Q3 2025 | |
| $10.9M | 1.71% | 0.56% | New | Q2 2026 | |
| $10.8M | 1.70% | 0.37% | -7.0% | Q4 2024 | |
| $10.7M | 1.68% | 0.26% | +214.2% | Q1 2025 | |
| $10.6M | 1.67% | 0.09% | +2.6% | Q3 2025 | |
| $10.2M | 1.61% | 0.45% | +33.4% | Q1 2025 | |
| $9.95M | 1.57% | 0.11% | +18.9% | Q2 2025 | |
| $9.86M | 1.55% | 0.12% | +17.1% | Q1 2025 | |
| $8.39M | 1.32% | 0.54% | +21.3% | Q4 2025 | |
| $7.92M | 1.25% | 0.22% | +38.2% | Q2 2025 | |
| $7.7M | 1.21% | 0.06% | +132.7% | Q1 2026 | |
| $7.63M | 1.20% | 0.34% | +24.7% | Q4 2025 | |
| $7.32M | 1.15% | 0.35% | +68.5% | Q4 2025 | |
| $7.31M | 1.15% | 0.07% | Not reported | Q3 2025 | |
| $7.09M | 1.12% | 0.83% | -3.9% | Q2 2024 | |
| $6.71M | 1.06% | 0.13% | New | Q2 2026 | |
| $6.67M | 1.05% | 0.01% | -72.9% | Q1 2026 | |
| $6.07M | 0.96% | 0.43% | -15.6% | Q4 2025 | |
| $5.35M | 0.84% | 0.27% | -6.3% | Q2 2025 | |
| $4.25M | 0.67% | 0.10% | +16.1% | Q1 2025 | |
| $2.96M | 0.47% | 1.79% | New | Q2 2026 | |
| $2.55M | 0.40% | 0.00% | Not reported | Q3 2020 | |
| $2.12M | 0.33% | 0.29% | New | Q2 2026 | |
| $1.6M | 0.25% | 0.24% | +23.8% | Q1 2025 | |
| $1.36M | 0.21% | 0.07% | New | Q2 2026 | |
| Q1 2026Reported May 15, 202634 positions | |||||
| $280M | 54.32% | Not reported | +44.5% | Q1 2022 | |
| $37.5M | 7.28% | 19.27% | -1.4% | Q4 2023 | |
| $25.4M | 4.92% | 0.04% | New | Q1 2026 | |
| $14.9M | 2.89% | Not reported | +66.7% | Q2 2025 | |
| $13.3M | 2.58% | 0.25% | Not reported | Q3 2019 | |
| $13.2M | 2.56% | 2.30% | Not reported | Q1 2022 | |
| $13.1M | 2.55% | 3.57% | Not reported | Q2 2018 | |
| $9.91M | 1.92% | 0.47% | +28.1% | Q4 2024 | |
| $7.98M | 1.55% | 0.09% | +31.2% | Q3 2025 | |
| $7.41M | 1.44% | 0.51% | +48.7% | Q4 2025 | |
| $7.16M | 1.39% | 0.87% | -36.4% | Q2 2024 | |
| $6.26M | 1.22% | 0.34% | +13.9% | Q1 2025 | |
| $5.65M | 1.10% | 0.10% | +13.2% | Q2 2025 | |
| $5.58M | 1.08% | 0.28% | +1.7% | Q4 2025 | |
| $5.43M | 1.05% | 0.11% | +31.5% | Q1 2025 | |
| $5.14M | 1.00% | 0.06% | -30.5% | Q4 2025 | |
| $5.08M | 0.99% | 0.07% | +66.5% | Q3 2025 | |
| $4.68M | 0.91% | 0.16% | +4.1% | Q2 2025 | |
| $4.42M | 0.86% | 0.29% | +16.5% | Q2 2025 | |
| $4.34M | 0.84% | 0.31% | +1.5% | Q3 2025 | |
| $3.78M | 0.73% | 0.19% | New | Q1 2026 | |
| STSLNOSoleno Therapeutics Inc | $3.42M | 0.66% | 0.20% | New | Q1 2026 |
| $3.39M | 0.66% | 0.04% | -25.5% | Q4 2024 | |
| $3.34M | 0.65% | 0.21% | +44.1% | Q4 2025 | |
| $3.32M | 0.64% | 0.44% | +72.5% | Q4 2025 | |
| $3.22M | 0.62% | 0.08% | Not reported | Q1 2025 | |
| $3.14M | 0.61% | 0.03% | New | Q1 2026 | |
| $2.28M | 0.44% | 0.25% | -31.9% | Q4 2025 | |
| $1.81M | 0.35% | 0.10% | Not reported | Q1 2025 | |
| $1.51M | 0.29% | 0.00% | Not reported | Q3 2020 | |
| $1.19M | 0.23% | 1.45% | New | Q1 2026 | |
| $1.16M | 0.23% | 0.20% | Not reported | Q1 2025 | |
| $827K | 0.16% | 0.04% | Not reported | Q3 2025 | |
| $295K | 0.06% | 0.24% | New | Q1 2026 | |
| Q4 2025Reported Feb 17, 202628 positions | |||||
| $286M | 60.30% | Not reported | +3.0% | Q1 2022 | |
| $27.3M | 5.75% | 19.55% | -1.9% | Q4 2023 | |
| $19.4M | 4.08% | 0.25% | Not reported | Q3 2019 | |
| $18.9M | 3.99% | 3.57% | Not reported | Q2 2018 | |
| $17.1M | 3.61% | 2.30% | Not reported | Q1 2022 | |
| $12.9M | 2.73% | Not reported | Not reported | Q2 2025 | |
| $10.2M | 2.15% | 1.36% | -3.8% | Q2 2024 | |
| $6.76M | 1.43% | 0.09% | New | Q4 2025 | |
| $6.62M | 1.40% | 0.37% | -19.7% | Q4 2024 | |
| $6.44M | 1.36% | 0.07% | +18.4% | Q3 2025 | |
| $5.4M | 1.14% | 0.30% | Not reported | Q1 2025 | |
| $4.92M | 1.04% | 0.05% | -42.0% | Q4 2024 | |
| $4.85M | 1.02% | 0.15% | +11.1% | Q2 2025 | |
| $4.52M | 0.95% | 0.32% | -19.4% | Q3 2025 | |
| RTRAPTRAPT Therapeutics, Inc. | $4.46M | 0.94% | 0.48% | New | Q4 2025 |
| $4.41M | 0.93% | 0.28% | New | Q4 2025 | |
| $4.22M | 0.89% | 0.08% | -11.8% | Q1 2025 | |
| $3.95M | 0.83% | 0.09% | +57.5% | Q2 2025 | |
| ATFOLDAmicus Therapeutics, Inc. | $3.71M | 0.78% | 0.08% | +115.1% | Q3 2025 |
| $3.3M | 0.69% | 0.25% | +5.7% | Q2 2025 | |
| $3.1M | 0.65% | 0.14% | New | Q4 2025 | |
| $2.93M | 0.62% | 0.34% | New | Q4 2025 | |
| $2.91M | 0.61% | 0.04% | +142.6% | Q3 2025 | |
| $2.89M | 0.61% | 0.37% | New | Q4 2025 | |
| $2.22M | 0.47% | 0.26% | New | Q4 2025 | |
| $2.19M | 0.46% | 0.00% | Not reported | Q3 2020 | |
| $1.72M | 0.36% | 0.34% | New | Q4 2025 | |
| APAVDLAvadel Pharmaceuticals PLC | $943K | 0.20% | 0.04% | New | Q4 2025 |
| Q3 2025Reported Nov 14, 202533 positions | |||||
| $227M | 30.33% | Not reported | +23.5% | Q1 2022 | |
| $39.2M | 5.24% | 19.94% | 0.0% | Q4 2023 | |
| $22M | 2.94% | 2.79% | Not reported | Q3 2019 | |
| $17M | 2.27% | 2.30% | Not reported | Q1 2022 | |
| $15.5M | 2.07% | 3.57% | Not reported | Q2 2018 | |
| $12.9M | 1.73% | Not reported | Not reported | Q2 2025 | |
| $7.85M | 1.05% | 0.46% | -4.0% | Q4 2024 | |
| $7.43M | 0.99% | 0.29% | -50.0% | Q2 2023 | |
| $6.44M | 0.86% | 1.93% | -24.8% | Q2 2024 | |
| $5.64M | 0.75% | 0.09% | +11.9% | Q4 2024 | |
| $4.86M | 0.65% | 0.36% | +3.5% | Q1 2025 | |
| $4.39M | 0.59% | 0.12% | +13.9% | Q2 2025 | |
| $3.82M | 0.51% | 1.30% | +6.5% | Q1 2025 | |
| $3.51M | 0.47% | 0.24% | +18.1% | Q2 2025 | |
| $3.11M | 0.42% | 0.40% | New | Q3 2025 | |
| $3.04M | 0.41% | 0.11% | +27.4% | Q1 2025 | |
| $2.82M | 0.38% | 0.16% | +61.3% | Q2 2025 | |
| $2.82M | 0.38% | 0.06% | New | Q3 2025 | |
| $2.69M | 0.36% | 0.05% | +473.3% | Q2 2025 | |
| $2.55M | 0.34% | 0.05% | New | Q3 2025 | |
| $2.26M | 0.30% | 0.00% | Not reported | Q3 2020 | |
| $1.84M | 0.25% | 0.05% | -46.7% | Q1 2025 | |
| $1.78M | 0.24% | 0.03% | +9.8% | Q2 2015 | |
| $1.34M | 0.18% | 0.00% | -16.9% | Q1 2025 | |
| $1.16M | 0.16% | 0.13% | -68.1% | Q1 2025 | |
| ATFOLDAmicus Therapeutics, Inc. | $955K | 0.13% | 0.04% | New | Q3 2025 |
| $860K | 0.11% | 0.02% | New | Q3 2025 | |
| $793K | 0.11% | Not reported | +183.7% | Q1 2022 | |
| $680K | 0.09% | 0.11% | -66.4% | Q4 2024 | |
| $668K | 0.09% | 0.12% | New | Q3 2025 | |
| $533K | 0.07% | 0.02% | New | Q3 2025 | |
| $504K | 0.07% | Not reported | New | Q3 2025 | |
| $376K | 0.05% | 0.01% | New | Q3 2025 | |
Premium opens every quarter this fund has filed